Natixis Advisors LLC Purchases 5,613 Shares of ResMed Inc. (NYSE:RMD)

Natixis Advisors LLC lifted its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 10.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 57,111 shares of the medical equipment provider's stock after acquiring an additional 5,613 shares during the period. Natixis Advisors LLC's holdings in ResMed were worth $13,061,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in RMD. True Wealth Design LLC lifted its stake in ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 110 shares during the last quarter. OFI Invest Asset Management bought a new stake in ResMed in the fourth quarter worth $39,000. BankPlus Trust Department bought a new stake in ResMed in the fourth quarter worth $44,000. Rosenberg Matthew Hamilton bought a new stake in ResMed in the fourth quarter worth $54,000. Finally, SBI Securities Co. Ltd. bought a new stake in ResMed in the fourth quarter worth $67,000. 54.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on RMD. Morgan Stanley began coverage on shares of ResMed in a research note on Wednesday. They issued an "overweight" rating and a $280.00 price target for the company. Stifel Nicolaus lowered their price target on shares of ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a research note on Wednesday, March 5th. Citigroup raised shares of ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Piper Sandler boosted their price target on shares of ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a research note on Friday, January 31st. Finally, Needham & Company LLC restated a "hold" rating on shares of ResMed in a research report on Friday, January 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $246.83.

Remove Ads

ResMed Trading Down 0.6 %

Shares of NYSE RMD traded down $1.35 during midday trading on Friday, hitting $219.77. 1,171,311 shares of the company traded hands, compared to its average volume of 959,797. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The stock has a 50-day moving average price of $234.91 and a 200 day moving average price of $239.02. The firm has a market cap of $32.28 billion, a P/E ratio of 25.95, a P/E/G ratio of 1.53 and a beta of 0.74.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 13th were given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.96%. The ex-dividend date was Thursday, February 13th. ResMed's dividend payout ratio is currently 25.03%.

Insider Activity at ResMed

In other ResMed news, insider Kaushik Ghoshal sold 9,113 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $235.40, for a total value of $2,145,200.20. Following the sale, the insider now owns 9,725 shares in the company, valued at approximately $2,289,265. This represents a 48.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now owns 77,218 shares in the company, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,940 shares of company stock worth $9,164,385 over the last 90 days. 0.71% of the stock is owned by company insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.